The RIGHT Choice trial, published in August 2024, evaluated the efficacy of ribociclib plus endocrine therapy (ET) versus combination chemotherapy (CT) as a first-line treatment in premenopausal women with clinically aggressive hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC). This head-to-head phase II study provided new insights into the optimal treatment approach for this aggressive disease subtype.
The study included 222 patients randomized 1:1 to receive either ribociclib with ET or a combination chemotherapy regimen. Results showed that ribociclib plus ET significantly improved progression-free survival (PFS) to 21.8 months compared to 12.8 months with CT (HR 0.61, P = 0.003). The overall response rates were 66.1% with ribociclib and 61.8% with CT, with fewer symptomatic adverse events reported in the ribociclib arm.
This study was led by Dr. Yen-Shen Lu, alongside a dedicated team of researchers committed to improving outcomes for patients with aggressive hormone receptor-positive breast cancer. Their efforts continue to shape the evolving landscape of breast cancer treatment.
For more details: https://lnkd.in/emDNPmH4
